Kevin Tang

Director

Kevin Tang (Director) filed 8 Form 4 reports in the trailing twelve months (8 purchases, 0 sales), most often in Aurinia Pharmaceuticals Inc. (AUPH). Across 8 priced purchase filings, the average 21-session return was +4.8% from execution and +6.8% from disclosure (delay-adjusted; derived). The largest single filing was $12.7M of AUPH (898,400 sh across 5 lots, as filed), executed Feb 27.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+4.8%

avg across 8 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+6.8%

same 8 filings, from disclosure

Filings, ttm

8 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$27.7M

shares × price, as filed

Last traded

Jul 17

Filed Jul 20

Median ADV $22.3M across their filed names

Impact on $10,000 · 12M

$12,441 (+24.4%)

S&P 500 $11,725 (+17.2%) · 7.2 pts ahead

Kevin Tang S&P 500

Compounded across filings from disclosure dates · past 12 months

Open performance→

Volume by month

Buys $64.9M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 8 filings

Sector per market data · by filing · past 12 months

Most traded names

AUPH

Aurinia Pharmaceuticals Inc. AUPH · 5 buys · 0 sells 5 filings BOLD

Boundless Bio, Inc. BOLD · 4 buys · 0 sells 4 filings FULC

Fulcrum Therapeutics, Inc. FULC · 2 buys · 0 sells 2 filings

Recent filings

AUPHPURCHASE Aurinia Pharmaceuticals Inc. View filing → $13.6M
1,300,000 sh across 3 lots
Exec Aug 1 2025
Filed Aug 5 2025 · 5:31 PM ET AUPHPURCHASE Aurinia Pharmaceuticals Inc. View filing → $12.7M
1,600,000 sh across 6 lots
Exec Feb 28 2025
Filed Mar 4 2025 · 5:30 PM ET AUPHPURCHASE Aurinia Pharmaceuticals Inc. View filing → $10.8M
1,200,000 sh across 3 lots
Exec Dec 5 2024
Filed Dec 9 2024 · 5:30 PM ET